LEIDEN, THE NETHERLANDS -- (MARKET WIRE) -- 12/29/2005 -- Biotech company Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM) (PHARM.AS) announced today that it has completed its human lactoferrin (hLF) filing for a Generally Recognized as Safe (GRAS) notification with the US Food and Drug Administration (FDA). Pharming has notified the FDA that its hLF is generally recognized as safe for use as an ingredient in functional foods. Pharming’s hLF GRAS notification has been reviewed by an independent scientific expert panel. After careful evaluation of numerous safety studies performed with Pharming’s hLF as well as of published scientific data, the expert panel has concluded that hLF is safe for its intended uses.
